Estrogen therapy ‘ups kidney stones risk’ in postmenopausal women
October 12th, 2010 - 2:50 pm ICT by ANIWashington, Oct 12 (ANI): A new report has suggested that the use of estrogen therapy is associated with an increased risk of developing kidney stones in postmenopausal women.
Using data from the national Women’s Health Initiative study, Naim M. Maalouf, of the University of Texas Southwestern Medical Center, Dallas, examined data from two trials: 10,739 postmenopausal women with hysterectomy who received either an estrogen-only treatment or matching placebo and 16,608 postmenopausal women without hysterectomy who received either an estrogen plus progestin treatment or matching placebo. Data were collected for an average of 7.1 years in the estrogen-only trial and 5.6 years for the estrogen plus progestin trial.
A total of 335 cases of kidney stones were reported in the active treatment groups, while 284 cases occurred in the placebo groups. The beginning demographic characteristics and risk factors for kidney stones were similar in the two groups, and the authors found that estrogen therapy was associated with a significant increase in risk of kidney stones. The corresponding annualized incidence rate per 10,000 women per year was 39 in the treatment group and 34 in the placebo group.
Development of kidney stones was five times more common in women with a history of kidney stones at the beginning of the study, but was not significantly altered by estrogen therapy. In this trial, estrogen therapy increased the risk of development of kidney stones irrespective of age, ethnicity, body mass index, prior hormone therapy use or use of coffee or thiazide diuretics.
The authors conclude that their results “indicate that estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women. The mechanisms underlying this higher propensity remain to be determined. In view of the sizable prevalence of nephrolithiasis in this segment of the population, these findings need to be considered in the decision-making process regarding postmenopausal estrogen use.”
The report has been published in the issue of Archives of Internal Medicine, one of the JAMA/Archives journals. (ANI)
- HRT raises risk of kidney stones - Oct 13, 2010
- Estrogen not linked to lung cancer mortality in postmenopausal women - Aug 14, 2010
- Postmenopausal hormone therapy 'ups breast cancer risk' - Oct 20, 2010
- How progesterone and estrogen increase breast cancer risk - Jan 19, 2011
- Estrogen alone can cut risk of breast cancer - Dec 10, 2010
- Combination menopausal hormone therapy ups heart disease risk - Feb 17, 2010
- Hormone therapy linked to increased breast cancer risk: Study - Aug 11, 2010
- Breast cancer risk varies among different progestins used in hormone replacement therapy - Aug 11, 2010
- Hormone therapies 'up breast cancer metastasis risk in post-menopausal women' - May 07, 2010
- Hormone replacement therapy 'increases lung cancer risk' - Mar 04, 2010
- Hormone therapy doubles breast cancer risk - Feb 05, 2009
- Hormone mix may cut breast cancer risk in menopausal women - Oct 20, 2009
- Menopausal hormone therapy 'ups ovarian cancer risk' - Nov 10, 2010
- Breast tenderness during hormone replacement therapy may indicate cancer risk - Oct 13, 2009
- Use of nitrates increases bone strength: study - Feb 23, 2011
Tags: body mass index, demographic characteristics, development of kidney, estrogen plus progestin, group development, health initiative, incidence rate, kidney stones, naim, nephrolithiasis, placebo group, placebo groups, postmenopausal women, southwestern medical center, southwestern medical center dallas, texas southwestern medical, texas southwestern medical center, thiazide diuretics, university of texas southwestern medical center, university of texas southwestern medical center dallas